Roche Holding AG

🇨🇭Switzerland

Country: 🇨🇭Switzerland

Ownership: Public

Established: 1896-01-15

Employees: 103.6K

Market Cap: $270.5B

Website: http://www.roche.com

Clinical Trials

A Study of Idasanutlin in Combination With Obinutuzumab in Relapsed/Refractory (R/R) Follicular Lymphoma (FL) and in Combination With Rituximab in R/R Diffuse Large B-Cell Lymphoma (DLBCL) Participants

Phase 1

Terminated

Conditions: Non-Hodgkin's Lymphoma

Interventions: Drug: Obinutuzumab
Drug: Idasanutlin
Drug: Rituximab

First Posted Date: 2015-12-09

Last Posted Date: 2020-05-18

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 25

Registration Number: NCT02624986

Locations: 🇺🇸
Mayo Clinic Arizona, Phoenix, Arizona, United States
🇩🇪
Charité Research Organisation GmbH Campus-Virchow-Klinikum, Berlin, Germany
🇰🇷
Samsung Medical Center, Seoul, Korea, Republic of

and more 21 locations

A Study of Recormon (Epoetin Beta) in Anemic Patients With Non-Myeloid Malignancy

Phase 4

Terminated

Conditions: Anemia

Interventions: Drug: Epoetin Beta

First Posted Date: 2015-12-08

Last Posted Date: 2016-11-02

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 10

Registration Number: NCT02624141

A Study on Rheumatoid Arthritis Patients Treated With Rituximab

Completed

Conditions: Rheumatoid Arthritis

Interventions: Drug: Rituximab

First Posted Date: 2015-12-04

Last Posted Date: 2016-12-13

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 81

Registration Number: NCT02622503

Clinical Progression of Mild to Moderate Idiopathic Pulmonary Fibrosis (IPF) Under a Therapy With Esbriet® (Pirfenidone)

Completed

Conditions: Idiopathic Pulmonary Fibrosis

Interventions: Drug: Pirfenidone

First Posted Date: 2015-12-04

Last Posted Date: 2017-02-28

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 12

Registration Number: NCT02622477

Locations: 🇩🇪
Praxis Dr. med. Wilhelm Ammenwerth, Bochum, Germany
🇩🇪
Universitätsklinikum Freiburg, Abteilung Pneumologie, Freiburg, Germany
🇩🇪
Kliniken der Stadt Köln gGmbH Krankenhaus Merheim, Köln, Germany

and more 14 locations

A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO5093151 in Patients With Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT).

Phase 1

Completed

Conditions: Glaucoma

Interventions: Drug: Placebo
Drug: Latanoprost
Drug: RO5093151

First Posted Date: 2015-12-04

Last Posted Date: 2018-03-14

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 45

Registration Number: NCT02622334

Locations: 🇺🇸
Cornerstone Eye Care, Div of Cornerstone Health Care, High Point, North Carolina, United States
🇸🇬
Singapore National Eye Centre; Glaucoma Department, Singapore, Singapore
🇺🇸
New York Eye and Ear Infirmary of Mt. Sinai; New York Glaucoma Research Institute, New York, New York, United States

and more 4 locations

A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Prophylactic Emicizumab Versus no Prophylaxis in Hemophilia A Participants With Inhibitors

Phase 3

Completed

Conditions: Hemophilia A

Interventions: Drug: Emicizumab
Drug: rFVIIa
Drug: aPCC

First Posted Date: 2015-12-04

Last Posted Date: 2021-06-24

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 113

Registration Number: NCT02622321

Locations: 🇺🇸
Children's Hospital Los Angeles, Los Angeles, California, United States
🇺🇸
Boston Childrens Hospital, Boston, Massachusetts, United States
🇯🇵
Hospital of the University of Occupational and Environmental Health,Japan, Kitakyushu-shi, Japan

and more 41 locations

Effect of Hepatic Impairment on the Pharmacokinetics of Alectinib

Phase 1

Completed

Conditions: Hepatic Impairment

Interventions: Drug: Alectinib

First Posted Date: 2015-12-03

Last Posted Date: 2018-08-24

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 28

Registration Number: NCT02621047

Locations: 🇸🇰
Summit Clinical Research s.r.o.; Oddelenie internej mediciny a klinickej farmakologie, Bratislava, Slovakia
🇨🇿
Pharmaceutical Research Associates CZ, s.r.o., Praha 7, Czechia

A Multiple-Dose Study of Oral Oseltamivir in Participants on Hemodialysis (HD) and Continuous Ambulatory Peritoneal Dialysis (CAPD)

Phase 1

Completed

Conditions: End Stage Renal Disease

Interventions: Drug: Oseltamivir

First Posted Date: 2015-12-01

Last Posted Date: 2016-02-15

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 24

Registration Number: NCT02617784

A Study of the Efficacy and Safety of Tocilizumab for Confirmed Rheumatoid Arthritis (RA) Participants in Clinical Practice

Terminated

Conditions: Rheumatoid Arthritis

Interventions: Other: No intervention

First Posted Date: 2015-11-26

Last Posted Date: 2018-10-18

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 8

Registration Number: NCT02616328

Locations: 🇸🇦
King Khaled Uni Hospital; Oncology, Riyadh, Saudi Arabia
🇸🇦
King Fahad Medical City; Gastroentrology, Riyadh, Saudi Arabia

A Study To Observe Treatment Patterns and Outcomes in Patients With HER2-Positive Unresectable Locally Advanced or Metastatic Breast Cancer

Withdrawn

Conditions: Breast Cancer, HER2 Positive Breast Cancer, Metastatic Breast Cancer, Locally Advanced Breast Cancer

Interventions: Other: No intervention

First Posted Date: 2015-11-26

Last Posted Date: 2017-02-23

Lead Sponsor: Hoffmann-La Roche

Registration Number: NCT02616224

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy